Basic and Diluted Loss Per Share |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Net Loss per Common Share: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Basic and Diluted Loss Per Share |
The weighted average number of shares used to calculate basic and diluted loss per share for the three-month periods ended March 31, 2026, and 2025 were as follows:
For the three months ended March 31, 2026 and 2025, deemed dividends of $449,000 and $384,000, respectively, were deducted from net loss to arrive at net loss available to common stockholders. The first quarter 2026 amount relates to the Series 2 Shares and consists of original issue discount accretion of $251,000, and the 9.5% preferred return accrual of $133,000. The first quarter 2025 amount consists of $301,000 of original issue discount accretion and the 10.0% preferred return accrual of $83,000 on the Series 1 Shares.
For the three months ended March 31, 2026 and 2025, approximately million and million shares, respectively, issuable upon the exercise or conversion of stock options, convertible preferred stock, and warrants outstanding were excluded from the calculation of diluted loss per share because such amounts were antidilutive.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||